BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 25406123)

  • 21. Expose your clinical thinking.
    Nat Biotechnol; 2004 Aug; 22(8):927. PubMed ID: 15286628
    [No Abstract]   [Full Text] [Related]  

  • 22. Predictable materiality: a need for common criteria governing the disclosure of clinical trial results by publicly-traded pharmaceutical companies.
    Cohen K; Cormier JW; Davar MV
    J Contemp Health Law Policy; 2013; 29(2):201-32. PubMed ID: 23837261
    [No Abstract]   [Full Text] [Related]  

  • 23. A future for regulatory science in the European Union: the European Medicines Agency's strategy.
    Hines PA; Janssens R; Gonzalez-Quevedo R; Lambert AIOM; Humphreys AJ
    Nat Rev Drug Discov; 2020 May; 19(5):293-294. PubMed ID: 32235873
    [No Abstract]   [Full Text] [Related]  

  • 24. Delays in completion and results reporting of clinical trials under the Paediatric Regulation in the European Union: A cohort study.
    Hwang TJ; Tomasi PA; Bourgeois FT
    PLoS Med; 2018 Mar; 15(3):e1002520. PubMed ID: 29494592
    [TBL] [Abstract][Full Text] [Related]  

  • 25. European drug agency to appeal ruling that it stop releasing trial data.
    Hawkes N
    BMJ; 2016 Sep; 354():i5331. PubMed ID: 27694255
    [No Abstract]   [Full Text] [Related]  

  • 26. [Drug control within the EEC I: coordination during the 1990's].
    Strandberg K
    Lakartidningen; 1992 Jan; 89(3):100-1. PubMed ID: 1734132
    [No Abstract]   [Full Text] [Related]  

  • 27. Medicines to remain with European Commission health directorate.
    Watson R
    BMJ; 2014 Oct; 349():g6514. PubMed ID: 25355097
    [No Abstract]   [Full Text] [Related]  

  • 28. Reform of drug regulation--beyond an independent drug-safety board.
    Ray WA; Stein CM
    N Engl J Med; 2006 Jan; 354(2):194-201. PubMed ID: 16407517
    [No Abstract]   [Full Text] [Related]  

  • 29. European drug agency under fire: critics charge that trial data are too inaccessible.
    Hampton T
    JAMA; 2011 Aug; 306(6):593-5. PubMed ID: 21828315
    [No Abstract]   [Full Text] [Related]  

  • 30. Drug development in oncology: a regulatory perspective.
    Augustus S
    Am J Ther; 2011 Jul; 18(4):323-31. PubMed ID: 20335790
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug trade bodies rally patient groups to deflect calls for full trial data.
    O'Dowd A
    BMJ; 2013 Jul; 347():f4702. PubMed ID: 23882001
    [No Abstract]   [Full Text] [Related]  

  • 32. Promoting Safe Early Clinical Research of Novel Drug Candidates: A European Union Regulatory Perspective.
    Ponzano S; Blake K; Bonelli M; Enzmann H;
    Clin Pharmacol Ther; 2018 Apr; 103(4):564-566. PubMed ID: 29105746
    [TBL] [Abstract][Full Text] [Related]  

  • 33. European Union pediatric legislation jeopardizes worldwide, timely future advances in the care of children with cancer.
    Rose K
    Clin Ther; 2014 Feb; 36(2):163-77. PubMed ID: 24529288
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drugmakers prefer silence on test data; firms violate US law by not registering trials.
    Vedantam S
    Washington Post; 2004 Jul; ():A1, A4. PubMed ID: 15290815
    [No Abstract]   [Full Text] [Related]  

  • 35. An Industry Perspective on the 2017 EMA Guideline on First-in-Human and Early Clinical Trials.
    DeGeorge J; Robertson S; Butler L; Derzi M; Stoch SA; Diaz D; Hartke J; Guzzie-Peck P; Mortimer-Cassen E; Bogdanffy M; Will Y; Greene N
    Clin Pharmacol Ther; 2018 Apr; 103(4):566-569. PubMed ID: 29285748
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Investment managers back greater transparency of clinical trials.
    Hawkes N
    BMJ; 2015 Jul; 351():h4002. PubMed ID: 26207007
    [No Abstract]   [Full Text] [Related]  

  • 37. European regulator is urged to release data on drugs approved in past 10 years.
    Kmietowicz Z
    BMJ; 2013 Sep; 347():f5905. PubMed ID: 24081901
    [No Abstract]   [Full Text] [Related]  

  • 38. Prozac papers.
    New Sci; 2005 Jan 8-14; 185(2481):4. PubMed ID: 15812956
    [No Abstract]   [Full Text] [Related]  

  • 39. Use of real-world evidence in postmarketing medicines regulation in the European Union: a systematic assessment of European Medicines Agency referrals 2013-2017.
    Brown JP; Wing K; Evans SJ; Bhaskaran K; Smeeth L; Douglas IJ
    BMJ Open; 2019 Oct; 9(10):e028133. PubMed ID: 31662354
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Medicine. Clinical trials and industry.
    Baird P; Downie J; Thompson J
    Science; 2002 Sep; 297(5590):2211. PubMed ID: 12351773
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.